Related Experiment Videos
Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer
R S Walters1, R L Theriault, F A Holmes
1Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030-4009.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|November 1, 1994
Abstract:
Ten patients with metastatic breast cancer were treated with a combination of recombinant alpha-interferon and recombinant interleukin-2. The toxicity of treatment was considerable, including one death on therapy. No objective responses were seen.